

IN THE CLAIMS

Please cancel claims 10, 11, 27 and 63 without prejudice

Please add new claims 64-72 as follows:

- 1-63. Cancelled
64. (New) A bispecific antibody with binding specificity for a first epitope and a second epitope wherein the first epitope is the epitope of a mammalian dipeptidyl peptidase IV recognized by E19 and E26.
65. (New) A bispecific antibody according to claim 64, wherein the second epitope is an epitope of seprase, an epitope of MT1-MMP, an epitope of MMP-2 or an epitope of $\alpha(3)\beta(1)$ -integrin.
66. (New) A bispecific antibody with binding specificity for a first epitope and a second epitope wherein the first epitope is the epitope of a mammalian dipeptidyl peptidase IV recognized by E19 and E26 and wherein the bispecific antibody inhibits cancer invasion.
67. (New) A bispecific antibody according to claim 66, wherein the second epitope is an epitope of seprase, an epitope of MT1-MMP, an epitope of MMP-2 or an epitope of $\alpha(3)\beta(1)$ -integrin.
68. (New) A bispecific antibody with binding specificity for a first epitope and a second epitope wherein the first epitope is the epitope of a mammalian dipeptidyl peptidase IV recognized by E19 and E26 and wherein the bispecific antibody inhibits cancer metastasis.
69. (New) A bispecific antibody according to claim 68, wherein the second epitope is an epitope of seprase, an epitope of MT1-MMP, an epitope of MMP-2 or an epitope of $\alpha(3)\beta(1)$ -integrin.

70. (New) A composition for inhibiting angiogenesis comprising an effective amount of a bispecific antibody according to claim 64 and a pharmaceutically acceptable carrier.
71. (New) A composition for inhibiting cancer invasion comprising an effective amount of a bispecific antibody according to claim 66 and a pharmaceutically acceptable carrier.
72. (New) A composition for inhibiting cancer metastasis comprising an effective amount of a bispecific antibody according to claim 68 and a pharmaceutically acceptable carrier.